针对免疫检查点抑制剂诱导的多基基隆神经病和心肌病的Efgartigimod:一个病例报告
Siqi Dong1, Zhangyang Wang1, Qin Wang1
1Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Experimental and therapeutic medicine
|September 3, 2025
概括
对于治疗罕见但严重的免疫相关不良反应 (irAEs),如由免疫检查点抑制剂 (ICI) 引起的多基隆性神经病和心肌病,efgartigimod具有前景. 这种方法为那些没有反应的患者提供了希望.
科学领域:
- 癌症学
- 免疫学
- 神经学
- 心脏病学
背景情况:
- 免疫检查点抑制剂 (ICI) 增强抗瘤免疫力,但可能导致严重的免疫相关不良事件 (irAEs).
- 包括多根性瘤神经病症 (PRN) 和心肌病症在内的irrAEs具有危及生命的风险.
- 像皮质类固醇和IVIG这样的标准治疗对这些IRA具有有限的疗效.
研究的目的:
- 报告一例成功治疗ICI引起的神经和心脏功能障碍的病例.
- 评估efgartigimod作为耐火性irrAEs的替代疗法的潜力.
主要方法:
- 一个63岁的胰腺癌患者的病例研究,在ICI治疗后出现PRN和心肌病.
- 最初使用IVIG和皮质类固醇治疗的结果是部分改善.
- 随后使用efgartigimod进行治疗.
主要成果:
- 埃夫加提莫德导致显著的神经恢复,使残疾和日常生活得分正常化.
- 临床改善与细胞因子和免疫球蛋白水平的降低相关.
- 患者在每周四次服用efgartigimod后出现了显著的康复.
结论:
- 在治疗ICI引起的PRN和心肌病方面,Efgartigimod具有治疗潜力,特别是在对标准治疗有抗性的患者中.
- 抗体介导的途径可能对这些irrAEs的发病具有关键作用.
- 需要进一步的研究来验证efgartigimod在更大的患者群体中的有效性和安全性.
更多相关视频
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
3.3K
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
1.9K
相关概念视频
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
27
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
27
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:30Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
01:17Pericarditis III: Medical Management
26
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
26